Frequently Asked Question
BPC-157 is not an FDA-approved drug and is not a lawful dietary ingredient. It was placed in Category 2 of the interim 503A compounding list in September 2023, then removed from that category in April 2026 and referred to an advisory committee. As of July 2026, no final rule has placed it on the approved 503A bulks list, so it has no cleared legal pathway for compounding.1 2 3
Get notified
The vote is advisory. The decision that shapes access comes later - if and when the FDA opens a formal public comment window. Most people never hear it opened. Join the list and we'll tell you the instant it does, with step-by-step instructions to file a comment that counts.